Chlamydophila pneumoniae IgM ELISA Kit (Human)
Referência OKNA00129
Tamanho : 96Wells
Marca : Aviva Systems Biology
Contactar o distribuidor local :
Telefone : +1 850 650 7790
Chlamydophila pneumoniae IgM ELISA Kit (Human) (OKNA00129)
| Datasheets/Manuals | Click here to download product manual. As variation between lots may occur, always reference the lot-specific manual received with each kit. |
|---|
| Predicted Species Reactivity | Human | |||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ELISA Kit Detection Method | Colorimetric, OD450 nm | |||||||||||||||||||||||||||||||||||||||
| ELISA Kit Duration | ~3 Hours | |||||||||||||||||||||||||||||||||||||||
| ELISA Kit Principle | Aviva Systems Biology Chlamydophila pneumoniae IgM ELISA Kit (Human) (OKNX00129) is based on standard reverse capture sandwich enzyme-linked immuno-sorbent assay technology. Chlamydophila pneumoniae antigen has been pre-coated and blocked in a 96-wellplate (12 x 8 Well Strips). Standards or test samples are added to the wells, incubated and washed. An HRP conjugated detector antibody specific for Human IgM is added, incubated and followed by washing. An enzymatic reaction is produced through the addition of substrate which is catalyzed by HRP generating a blue color product that changes to yellow after adding acidic stop solution. The density of yellow coloration is read by absorbance at 450 nm and is qualitatively proportional to the amount of sample anti-Chlamydophila pneumoniae IgM captured the in well. | |||||||||||||||||||||||||||||||||||||||
| ELISA Kit Reproducibility |
| |||||||||||||||||||||||||||||||||||||||
| ELISA Kit Component |
| |||||||||||||||||||||||||||||||||||||||
| Reconstitution and Storage | Store as indicated in product manual. | |||||||||||||||||||||||||||||||||||||||
| Sample Type | Serum, Plasma | |||||||||||||||||||||||||||||||||||||||
| Sensitivity | Sensitivity is determined as the probability of the assay indicating a positive score in samples with the specific analyte present: > 85.7% | |||||||||||||||||||||||||||||||||||||||
| Specificity | Specificity is determined as the probability of the assay indicating a negative score in samples absent of the specific analyte: > 98% | |||||||||||||||||||||||||||||||||||||||
| Assay Info | Assay Methodology: Quantitative Reverse Capture Sandwich ELISA |
| Alias Symbols | CPN |
|---|---|
| Protein Name | Chlamydophila pneumoniae IgM |
| Description of Target | Chlamydiaceae are obligate intracellular bacteria characterized by a biphasic life cycle consisting of elementary bodies (EB) and reticulate bodies (RB). The elementary body is the metabolically-inactive infectious form and is adapted for survival outside the host cell. After internalization by receptor-mediated endocytosis, the EB transforms into a reticulate body and begins to replicate within the endosome. The reticulate bodies are dependent on the host cell since they are unable to generate ATP and are incapable of de novo nucleotide biosynthesis. After growth and division, the products of the RB condense to form infectious EB. In 1999 the genus Chlamydia was divided into two genera: Chlamydia and Chlamydophila. C. pneumoniae was originally called the TWAR strain from the names of the two original isolates - Taiwan (TW-183) and an acute respiratory isolate designated AR-39. It is now considered a separate species of chlamydia. In 1999 the renaming as Chlamydophila pneumoniae was proposed. Currently both names are in use by different authors. C. pneumoniae is the causative agent of an atypical pneumonia similar to those caused by Mycoplasma pneumoniae and Legionella pneumoniae. In addition it can cause a pharyngitis, bronchitis and sinusitis. Moreover, C. pneumoniae has been reported as a possible cause of atherosclerosis and central nervous system (CNS) disorders. The organism is transmitted person-to-person by respiratory droplets. The incubation period may range from 1-4 weeks. Upper respiratory signs and symptoms, such as rhinitis, sore throat, or hoarseness, may be reported initially. These signs and symptoms may then subside over days to weeks, followed by the onset of cough, resulting in a biphasic pattern of illness symptoms. Symptoms due to C. pneumoniae respiratory infections may be of prolonged duration, with persistence of cough and malaise for several weeks or months despite appropriate antibiotic therapy. |